For the treatment of hospital-acquired pneumonia/ ventilator associated pneumonia caused by Gram-negative bacteria: ZAVICEFTA (ceftazidime and avibactam)
Pfizer has a strong portfolio in licensed products for the treatment of pneumonia, including ZAVICEFTA® (ceftazidime and avibactam) and ZINFORO® (ceftaroline fosamil).*†1,2 ZAVICEFTA® is indicated for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)1.
HAP/VAP is:
- A frequent cause of mortality, with rates ranging from approximately 20-70% 3,4
- Predominantly caused by increasingly resistant aerobic Gram-negative bacteria which are difficult to treat 5-9
ZAVICEFTA: an antipseudomonal cephalosporin combined with a novel β-lactamase inhibitor, with bactericidal activity against difficult-to-treat infections due to aerobic Gram-negative bacteria frequently encountered in HAP/VAP, including:10-14
- Pseudomonas aeruginosa (including many ceftazidime- resistant strains)
- ESBL-producing Enterobacteriaceae
- Carbapenem-resistant Enterobacteriaceae
Footnotes:
*ZAVICEFTA® is indicated for the treatment of the following infections in adults: Complicated urinary tract infections, including pyelonephritis; Complicated intra-abdominal infections; Hospital-acquired pneumonia, including ventilator-associated pneumonia; Infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.1
†Zinforo® is indicated for the treatment of patients with complicated skin and soft tissue infections and community-acquired pneumonia.2
Abbreviations:
ESBL, extended-spectrum b-lactamase; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia.
References:
1.ZAVICEFTA. Summary of Product Characteristics; 2. ZINFORO. Summary of Product Characteristics; 3. American Thoracic Society; Infectious Diseases Society of America. Am J Respir Crit Care Med 2005;171:388–416; 4. Chastre J, Fagon J-Y. Am J Respir Crit Care Med 2002;165:867–903; 5. Jones RN. Clin Infect Dis 2010;51 (Suppl 1):S81–7; 6. Brusselaers N, et al. Ann Intensive Care 2011;1:47; 7. Centers for Disease Control and Prevention (CDC). Gram-negative bacteria infections in healthcare settings. Available at: https://www.cdc.gov/hai/organisms/gram-negative-bacteria.html (last accessed April 2020); 8. Bush K. Crit Care 2010;14:224; 9. Ventola CL. P T 2015;40:277–83; 10. Torres A, et al. Lancet Infect Dis 2017 Dec 15; doi 10.1016/S1473–3099(17)30747–8 [Epub]; 11. Torres A, et al. Lancet Infect Dis 2017 Dec 15; doi 10.1016/S1473–3099(17)30747–8 [Epub] (supplementary appendix); 12. de Jonge BLM, et al. Antimicrob Agents Chemother 2016;60:3163–9; 13. Hackel M, et al. Antimicrob Agents Chemother 2016;60:4677–83; 14. Karlowsky J, et al. Antimicrob Agents Chemother 2016;60:2849–57
Prescribing Information
Zavicefta▼ (ceftazidime avibactam) Prescribing Information
ZAVICEFTA® 2 g/0.5 g Powder for Concentrate for Solution for Infusion
Legal Category: Prescription Only Medicine (POM)
NHS Price: 10 vial pack £857.00.
Click here for the Summary of Product Characteristics
Meronem IV (meropenem) Prescribing Information
Meronem IV 1g
Legal Category: Prescription Only Medicine (POM).
NHS Price: 10 vial pack £206.28
Click here for the Summary of Product Characteristics
Meronem IV 500mg
Legal Category: Prescription Only Medicine (POM).
NHS Price: 10 vial pack £103.14
Click here for the Summary of Product Characteristics
Tygacil® (tigecycline) Prescribing Information
Tygacil® 50 mg Powder for Solution for Infusion
Legal Category: Prescription Only Medicine (POM)
NHS Price: 10 vial pack £323.10
Click here for the Summary of Product Characteristics
Tazocin® (piperacillin sodium, tazobactam sodium) Prescribing information
Tazocin® 2 g/0.25 g Powder for Solution for Infusion
Legal Category: Prescription Only Medicine (POM)
NHS Price: 1 vial pack £7.65
Click here for the Summary of Product Characteristics
Tazocin® 4 g/0.5 g Powder for Solution for Infusion
Legal Category: Prescription Only Medicine (POM)
NHS Price: 1 vial pack £15.17
Click here for the Summary of Product Characteristics
PP-ZVA-GBR-1058. December 2020